The company anticipates generating $75 million in gross proceeds from the offering, which is scheduled to close on or about Monday. Capital influx comes from a mix of new and established investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. Alector intends to allocate the funds toward general corporate purposes to support its ongoing operations and development pipeline. This latest financing milestone arrives as the stock sustains a 39% rally over the past three months, reflecting a sustained period of growth for the biotech developer.
Alector Secures $75 Million in Premium Stock Offering
Alector shares climbed 6% to $2.03 in morning trading after the biotechnology firm priced a 36.6 million share offering at $2.05 apiece. This move represents a 7.3% premium over Thursday’s closing price, signaling strong market confidence despite the dilution of existing common stock.
Comments (0)
No comments yet. Be the first!